Today, Axsome Therapeutics released fourth quarter 2025 financial results. Another impressive quarter as the company is getting closer to becoming profitable, on a cash and earnings per share basis. 4th quarter highlights below.
- FDA decision date of 4/30/26 for Alzheimer's Disease Agitation
- $196 million in fourth quarter total revenue
- 65% year over year revenue growth
- 322.9 million in cash
- 50,882 million shares outstanding
Daily chart below of Axsome Therapeutics. Thank you for reading.
